Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.42 USD
+0.11 (8.40%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.42 0.00 (0.00%) 5:34 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Akebia Therapeutics, Inc. [AKBA]
Reports for Purchase
Showing records 1 - 20 ( 81 total )
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
FDA Approves Vafseo For Anemia in CKD on Dialysis; Akebia to Launch Vafseo in January 2025; Raise PT to $6.00
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
4Q Recap; We Anticipate Vadadustat''s U.S. Approval By March 27 PDUFA Date
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Balance Sheet Strengthened Within Just Two Months of Potential FDA Approval of Vadadustat; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
3Q Recap; Expecting Vadadustat''s U.S. Approval By March 27, 2024; Increasing PT to $5 on New Estimated Pricing
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Vadadustat NDA Resubmission Formally Accepted; We Expect Approval by March 27, 2024, PDUFA Date; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Akebia Resubmits Vadadustat NDA; We Expect FDA Approval Near the End of March 2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Vadadustat Now Approved in Australia; NDA Resubmission For U.S. Approval Remains on Target by End of 3Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
FDA Meeting Minutes Confirm Regulatory Path; We Now Anticipate Vadadustat Approval in March 2024; Upgrade to Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Delayed 10-Q Filing Should Not Impact 2023 Auryxia Sales Guidance, Vadadustat NDA Resubmission or Cash Runway
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Vafseo''s European Market Opportunity Expands With Swissmedic Approval; Maintain Neutral Ahead of FDA Type A Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Akebia Appoints New CFO; Awaiting Type A Meeting Minutes to Confirm Vadadustat''s U.S. Regulatory Path; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Last Settlement Reached for Generic Auryxia ANDA; Next Catalyst is Vadadustat FDA Type A Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
FDA Offers a Straightforward Path for Vadadustat; Akebia to Resubmit NDA in 2H23, Rekindling Hopes of FDA Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Vafseo''s Launch in Europe Licensed to Experienced Partner; FDRR Response Remains Key Catalyst; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
MHRA Approval Adds Another Feather to Vafseo''s Cap For Partnership Discussions; Maintain Neutral Ahead of FDRR Response
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
1Q Recap; FDRR Response Expected Within 30 Days to Determine Vadadustat''s U.S. Regulatory Path; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Vafseo Approved in EU As Anticipated; We Expect Partnership Talks to Accelerate; Increasing PT to $2; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Latest Dialog With OND on Vadadustat FDRR Was Productive; Response Expected in 2Q23; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
4Q Recap; Vadadustat Approaches Multiple Regulatory Decisions; We Expect FDRR Outcome in Mid-2023; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Positive CHMP Opinion For Vafseo in Europe; We Anticipate a Commercial Partnership Post-Approval; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E